Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
Last trade$10.49
Day change-$0.49 (-4.46%)
Day range$10.27 – $11.37
Volume126,232
Market cap$67M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$67.16M
Price / earnings
—
Price / book
-0.55×
Price / sales
0.86×
EV / sales
0.68×
EV / EBITDA
-0.46×
Profitability
Earnings per share
-$20.45
Return on assets
-194.4%
Return on equity
101.86%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0.3×
Current ratio
0.6×
Quick ratio
0.6×
Cash ratio
0.51×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$156.04M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GOSS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$38.43M
$9.24M
$16.96M
$13.8M
$13.29M
$11.49M
$9.89M
$9.38M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$38.43M
$9.24M
$16.96M
$13.8M
$13.29M
$11.49M
$9.89M
$9.38M
Selling, general and administrative
$9.64M
$8.9M
$18.75M
$10.9M
$9.39M
$8.68M
$8.66M
$9.4M
Research and development
$21.6M
$26.41M
$43.08M
$48.93M
$53.02M
$41.58M
$38.04M
$36.11M
Total operating expenses
$31.24M
$35.31M
$61.82M
$59.84M
$62.41M
$50.25M
$46.7M
$45.51M
Operating income
$7.2M
-$26.07M
-$44.87M
-$46.04M
-$49.11M
-$38.77M
-$36.81M
-$36.13M
Interest expense
-$2.46M
-$2.71M
-$2.76M
-$2.75M
-$2.75M
-$2.74M
-$2.75M
-$2.74M
Income before taxes
-$48.07M
$16.9M
-$46.66M
-$47.33M
-$48.22M
-$38.27M
-$36.64M
-$35.44M
Income taxes
$0
$0
$0
-$88K
$0
$0
$0
-$2.41M
Net income
-$48.07M
$16.9M
-$46.66M
-$47.24M
-$48.22M
-$38.27M
-$36.64M
-$33.03M
Net income attributable to common shareholders
-$48.07M
$16.9M
-$46.66M
-$47.24M
-$48.22M
-$38.27M
-$36.64M
-$33.03M
EBITDA
$7.2M
-$26.07M
-$44.86M
-$52.33M
-$49.11M
-$38.76M
-$36.8M
-$45.76M
Basic earnings per share
-$7.36
$4.00
-$16.00
-$16.29
-$16.92
-$13.60
-$12.80
-$11.66
Diluted earnings per share
-$7.36
-$6.40
-$16.00
-$16.29
-$16.92
-$13.60
-$12.80
-$12.33
Recent news
Company coverage with links to the original publishers.
Gossamer Bio (GOSS) has gained 30.3% over the past four weeks and trades at $10.98. Wall Street analysts have a mean price target of $83.4, suggesting potential upside of 659.6%. The stock holds a Zacks Rank #2 (Buy) rating, supported by strong earnings estimate revisions with consensus estimates up 35.9% over the past month. However, the article cautions that price targets should not be the sole basis for investment decisions, as analysts often set overly optimistic targets.
TG Therapeutics (TGTX) reported Q3 2026 earnings of $0.35 per share, beating consensus estimates of $0.28, with revenues of $259.94 million exceeding expectations by 5.17%. The stock has gained 100.7% year-to-date and received a Zacks Rank #1 (Strong Buy) rating based on favorable estimate revisions. The company's Medical - Biomedical and Genetics industry ranks in the top 43% of Zacks industries.
Over 100 pharmaceutical companies are actively developing 110+ pipeline hypertension drugs, with approximately 40+ in late-stage development. Key players include Gossamer Bio, Alnylam Therapeutics, Roche, GSK, and others pursuing novel mechanisms like RNA interference and CRAC channel inhibitors. Recent developments include FDA acceptance of lorundrostat's NDA, initiation of zilebesiran's Phase III cardiovascular outcomes trial, and multiple clinical advances in emerging therapies targeting uncontrolled and resistant hypertension.
The Schall Law Firm is seeking investors who purchased Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026 to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements regarding its Phase 3 PROSERA study design, specifically concealing adverse facts about placebo response controls at certain testing sites.
A securities class action lawsuit has been filed against Gossamer Bio (GOSS) alleging executives concealed placebo response risks in the Phase 3 PROSERA trial for seralutinib. The trial failed to meet its primary endpoint on February 23, 2026, causing an 80% stock price decline. The complaint claims management misled investors about trial design and patient recruitment despite knowing of significant placebo effects, particularly at Latin American sites.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.